SGLT-2 inhibitors were linked to lower risk for autoimmune rheumatic diseases in those with diabetes compared with sulfonylureas.

Despite being a first-line treatment for CHE, nearly 40% of patients treated with TCS had inadequate treatment response or contraindications to TCS.

Patients use AI self-diagnosis tools because this technology offers quick answers, helps overcome difficulties in accessing care, appeals to patients who distrust health care providers or wish to ...